title: [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD].
abstract: BACKGROUND
  In COPD, inhaler choice should be based on the likelihood that the patient will be able to use the device correctly in order to favour adherence and compliance, and therefore treatment efficacy. SATE OF THE ART: Performances of usual inhalers are limited by the necessity of a good coordination of patient inspiration and inhaler activation (pressurized metered dose inhalers), or a sufficient inspiratory flow (dry powder inhalers). Respimat®, the first "Soft Mist™ inhaler" (SMI), releases the drug solution as a low and sustained soft mist, so that lung deposition is both improved and reproducible.
  
  
  CONCLUSIONS
  In clinical studies, Respimat® has been shown to allow equivalent bronchodilator response and tolerability to metered dose or dry powder inhalers, but with lower doses of active drugs. Furthermore, studies assessing inhaler preference in COPD showed that patients preferred Respimat® to usual inhalers.
  
  
  CONCLUSIONS
  Respimat® SMI offers new perspectives for the management of chronic respiratory diseases, particularly in newly diagnosed or poorly compliant patients.
authors.affiliation: Inserm U618, Service de Pneumologie, Hôpital Bretonneau, CHU de Tours, 2 Boulevard Tonnellé, 37044 Tours, France.
authors.forename: A-C
authors.initials: AC
authors.lastname: Henriet
authors.forename: S
authors.initials: S
authors.lastname: Marchand-Adam
authors.forename: J
authors.initials: J
authors.lastname: Mankikian
authors.forename: P
authors.initials: P
authors.lastname: Diot
mesh_terms: D000280:Administration, Inhalation; D058666:Adrenergic beta-2 Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000336:Aerosols; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy; D001986:Bronchial Spasm / Q000139:chemically induced; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D058995:Dry Powder Inhalers; D004867:Equipment Design; D006801:Humans; D001239:Inhalation; D008168:Lung / Q000187:drug effects; D036501:Metered Dose Inhalers; D009330:Nebulizers and Vaporizers; D009960:Oropharynx / Q000187:drug effects; D010349:Patient Compliance; D017060:Patient Satisfaction; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D000336:Aerosols; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents